CRISPR-Cas9 delivery in solid tumors
A review of lipid nanoparticle and viral vector approaches, with implications for clinical translation in pediatric oncology.
Background
Targeted gene editing has progressed rapidly since the first clinical trials in 2019. Despite proven efficacy in liquid tumors, solid-tumor delivery remains the central bottleneck. 7 papers cited
The field has converged on three primary delivery modalities: AAV vectors, lentiviral systems, and lipid nanoparticles. Each comes with tradeoffs in payload capacity, immunogenicity, and tropism.

